UK regulator approves Pfizer`s hair loss drug
European Commission Approves Pfizer’s LITFULO™ for Adolescents and Adults With Severe Alopecia Areata
New York, July 21, 2023 — Pfizer Inc. (NYSE: PFE) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion for LITFULO™ (ritlecitinib), an oral treatment, recommending marketing authorization of once-daily 50 mg for individuals 12 years of age and older with severe alopecia areata.
Pfizer has announced that the US Food and Drug Administration (FDA) has approved its Litfulo (ritlecitinib) for patients over the age of 12 with severe alopecia areata. The drug is a once-daily oral treatment, with an approved and recommended dose of 50mg. It is also the first and only FDA-approved treatment for adolescents with severe alopecia areata.
June 23 (Reuters) - The U.S. Food and Drug Administration has approved Pfizer Inc's (PFE.N) drug to treat hair loss caused by an autoimmune disease, the company said on Friday.